2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5780 Multi-center Phase II trial of iberdomide and SQ daratumumab as post-transplant maintenance in patients with multiple myeloma (the IBEX trial): Updated results of a pre-planned safety analysis and interim efficacy results

Andrew Kin, MD, Craig Cole I, MD2, Shiva Shrotriya, MD, MPH3, Malini Surapaneni, MD4, Attaya Suvannasankha, MD5, Marcella Kaddoura, MD6, Abhinav Deol, MD7, Amy Blake, NP8, Joseph Ellul, NP9, Katelyn Staub, RN10, Deborah Hackstock, BSN, RN, OCN11, Ryan Gennette, DNP, NP-C12, Christiane Houde, BS13, Erik Carr14, Sarah Phillips, BS15, Julie Boerner, PhD16, Hyejeong Jang, MS17, Seongho Kim, PhD18, Jeffrey A. Zonder, MD19
1 Karmanos Cancer Institute, Detroit, Michigan, United States
2 Karmanos Cancer Institute, Detroit, Michigan, United States
3 Karmanos Cancer Institute, Detroit, Michigan, United States
4 Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
5 Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
6 Karmanos Cancer Institute, Detroit, Michigan, United States
7 Karmanos Cancer Institute, Detroit, Michigan, United States
8 Karmanos Cancer Institute, Detroit, Michigan, United States
9 Karmanos Cancer Institute, Detroit, Michigan, United States
10 Karmanos Cancer Institute, Detroit, Michigan, United States
11 Karmanos Cancer Institute, Detroit, Michigan, United States
12 Karmanos Cancer Institute, Detroit, Michigan, United States, Michigan State University, East Lansing, Michigan, United States
13 Karmanos Cancer Institute, Detroit, Michigan, United States
14 Karmanos Cancer Institute, Detroit, Michigan, United States
15 Karmanos Cancer Institute, Detroit, Michigan, United States
16 Karmanos Cancer Institute, Detroit, Michigan, United States
17 Karmanos Cancer Institute, Detroit, Michigan, United States
18 Karmanos Cancer Institute, Detroit, Michigan, United States
19 Karmanos Cancer Institute, Detroit, Michigan, United States

Intro/Background: Maintenance therapy after autologous stem cell transplant (ASCT) improves progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Lenalidomide (LEN) is a standard maintenance therapy. Addition of an anti-CD38 antibody such as daratumumab (DARA) increases minimal residual disease negative [MRD(-)] responses and further improves outcomes. Iberdomide (IBER) is a Cereblon E3-ligase modulator (CELMoD) with a distinct binding profile compared to LEN which results in enhanced target protein degradation, increased immune activation, and direct anti-MM activity (including LEN-resistant disease). IBER and DARA demonstrate synergistic anti-MM activity, and in a recent phase III trial, the combination of IBER, DARA and dexamethasone (DEX) had superior MRD-negativity rates compared to bortezomib, DARA, and DEX. IBEX is a multicenter phase II trial evaluating IBER plus DARA as post-ASCT maintenance. Herein, we report a pre-specified safety analysis and preliminary efficacy data.

Methods: Pts with MM who received anti-CD38-containing induction therapy followed by ASCT were eligible. At the outset of the study, inclusion criteria included documented post-ASCT MRD(+) status by ClonoSEQ NGS; this was later revised to include MRD(+) and MRD(-) pts, with MRD assessment by either ClonoSEQ NGS or by Next Generation Flow cytometry (NGF). IBER was given on days 1–21 of 28-day cycles (max 26 cycles) starting at 1 mg/d, later amended to 0.75 mg/d following the dose-optimization results of the EXCALIBER trial. DARA 1800 mg SQ was administered qw (C1–2), q2w (C3–6), then q4w (C7+). All pts received aspirin unless anticoagulated, and anti-viral prophylaxis. The original primary endpoint, MRD conversion from (+) to (-) by ClonoSEQ NGS (10^-5) by 12 mos, was revised to 12-mos sustained MRD negativity (10^-5 using either NGS or NGF). This modification was made due to a growing appreciation that sustained MRD-negative status is a stronger predictor of future disease control than simply attaining MRD-negativity at any one time point. Forty-two MRD-evaluable pts are required to assess the primary endpoint. Secondary endpoints: MRD conversion, 12- & 24-mo PFS/OS, change in IMWG response, HRQoL, and safety. Safety monitoring: continuously assessed Pocock-type stopping boundary defined by grade(Gr)3+ non-heme or Gr4+ heme adverse events (AEs) at least possibly related to treatment.

Results: As of July 16th, 2026, 21 pts have begun treatment. Enrolled pts: 11 M/10 F, 18 White/ 3 Black or African American. Median age: 61 (range 26-72). 8 pts had high risk (HR) MM at diagnosis: 7 HR-FISH, 1 with elevated LDH. Initial IBER dose was 1.0 mg in 10 pts and 0.75 mg in 11. Median treatment duration: 6 cycles (range, 1–25). The stopping boundary was 11 events. Five pts experienced 8 treatment-related Gr3 nonhematologic AEs: 5 infections (3 in one pt), 1 fever without definite infection, 1 rash, 1 second malignancy. No Gr4 treatment-related hematologic AEs occurred, although the most common treatment-related AE was neutropenia (9 pts; all Gr3). Nine pts experienced infections, in most cases multiple instances over the course of therapy. 87% of all infections were Gr1/2.  Upper respiratory infections accounted for 59% of all infections. Diarrhea was uncommon and mild (5 pts, all Gr1). Eight pts reported worsening neuropathy (Gr1 in 7/8 cases; attributed to IBER in 5/8 cases). One Gr2 thromboembolic event was observed. The one documented second malignancy was a case of EBV(+) classical Hodgkin lymphoma found during end-of-study PET/CT imaging after 24 cycles of therapy. Six pts required dose reductions of IBER. Fifteen pts were MRD(+) at enrollment; among 9 evaluable at 12 mos, 5 converted to MRD(-), 4 remained MRD(+). IMWG response status (PR/VGPR/CR+/unknown) at enrollment: 4/11/5/1. Five pts improved their IMWG response category: PR to CR+ in 2, PR to VGPR in 1, VGPR to CR+ in 2. Only 1 pt developed progressive MM while on IBER/DARA maintenance: a new PET/CT-detected bone lesion despite concurrent MRD-negative marrow assessment.

Conclusions: Post-ASCT maintenance with IBER plus DARA is feasible and toxicity is manageable. Neutropenia was manageable at the doses used in IBEX. Improvements in IMWG response and MRD conversion were observed even after pre-ASCT quadruplet induction. Enrollment is ongoing. Updated safety and efficacy results will be presented.

Andrew Kin, MD: No relevant conflicts of interest to declare.